7,642 results match your criteria t1d


The Role of Programmed Death-1 in Type 1 Diabetes.

Curr Diab Rep 2021 May 6;21(6):20. Epub 2021 May 6.

Department of Medicine, Center for Immunology, University of Minnesota Medical School, 2101 6th St SE, Wallin Medical Biosciences Building, 3-146, Minneapolis, MN, 55455, USA.

Purpose Of Review: Programmed death-1 (PD-1) is an inhibitory receptor that controls T and B cell proliferation and function through interacting with its ligand PD-L1 or PD-L2. PD-1/PD-L1 blockade reboots anti-tumor immunity and is currently used to treat > 15 different types of cancer. However, the response rate is not at 100% and some patients relapse. Read More

View Article and Full-Text PDF

Tetrahedral Framework Nucleic Acids Induce Immune Tolerance and Prevent the Onset of Type 1 Diabetes.

Nano Lett 2021 May 6. Epub 2021 May 6.

State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China.

A failure in immune tolerance leads to autoimmune destruction of insulin-producing β-cells, leading to type 1 diabetes (T1D). Inhibiting autoreactive T cells and inducing regulatory T cells (Tregs) to re-establish immune tolerance are promising approaches to prevent the onset of T1D. Here, we investigated the ability of tetrahedral framework nucleic acids (tFNAs) to induce immune tolerance and prevent T1D in nonobese diabetic (NOD) mice. Read More

View Article and Full-Text PDF

Neoepitopes in Type 1 Diabetes: Etiological Insights, Biomarkers and Therapeutic Targets.

Front Immunol 2021 19;12:667989. Epub 2021 Apr 19.

Janssen Research and Development, LLC, Raritan, NJ, United States.

The mechanisms underlying type 1 diabetes (T1D) pathogenesis remain largely unknown. While autoantibodies to pancreatic beta-cell antigens are often the first biological response and thereby a useful biomarker for identifying individuals in early stages of T1D, their role in T1D pathogenesis is not well understood. Recognition of these antigenic targets by autoreactive T-cells plays a pathological role in T1D development. Read More

View Article and Full-Text PDF

FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction.

Endocrinology 2021 May 5. Epub 2021 May 5.

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.

Fibroblast growth factor 21 (FGF21) is a member of the fibroblast growth factor (FGF) family of proteins. The biological activity of FGF21 was first shown to induce insulin independent glucose uptake in adipocytes through the GLUT1 transporter. Subsequently, it was shown to have effects on the liver to increase fatty acid oxidation. Read More

View Article and Full-Text PDF

Sleep-wake characteristics, daytime sleepiness, and glycemia in young adults with type 1 diabetes.

J Clin Sleep Med 2021 May 5. Epub 2021 May 5.

School of Nursing and School of Medicine, Yale University, West Haven, Connecticut.

Study Objectives: The purpose of this study was to describe objective sleep-wake characteristics and glycemia over 7 - 14 days in young adults with type 1 diabetes (T1D). Additionally, person level associations among objective sleep-wake characteristics (total sleep time, sleep variability, and sleep fragmentation index), daytime sleepiness, and glycemia (glycemic control and glucose variability) were examined.

Methods: In this cross-sectional study, objective sleep-wake characteristics were measured via actigraphy and glucose variability via continuous glucose monitoring (CGM) over 6-14 days. Read More

View Article and Full-Text PDF

Associated Autoimmunity in Type 1 Diabetes and Latent Autoimmune Diabetes of Adults: The Role of Glutamic-Acid Decarboxylase Autoantibodies.

Diabetes Res Clin Pract 2021 May 1:108847. Epub 2021 May 1.

Diabetes and Metabolism Clinic, 2(nd) Department of Pediatrics, National and Kapodistrian University of Athens, "P&A Kyriakou" Children's Hospital, Athens, Greece.

Aims: To determine the prevalence of Associated Autoimmune Diseases (AADs) in Latent Autoimmune Diabetes of Adults (LADA) versus autoimmune Type 1 Diabetes (T1D) and the role of glutamic-acid decarboxylase antibodies (GADA) and other factors.

Methods: Adults with autoimmune diabetes mellitus (DM) were recruited from the Diabetes Center of Nikaia-Piraeus Hospital. Demographic and clinical parameters were recorded and anti-pancreatic and organ-specific antibodies were measured. Read More

View Article and Full-Text PDF

Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients.

Arch Endocrinol Metab 2021 Apr 29. Epub 2021 Apr 29.

Departamento de Nutrologia e Diabetes, Universidade Federal do Rio de Janeiro, RJ, Brasil.

Objective: Adipose tissue-derived stromal/stem cells (ASCs) and vitamin D have immunomodulatory actions that could be useful for type 1 diabetes (T1D). We aimed in this study to investigate the safety and efficacy of ASCs + daily cholecalciferol (VIT D) for 6 months in patients with recent-onset T1D.

Methods: In this prospective, dual-center, open trial, patients with recent onset T1D received one dose of allogenic ASC (1 × 10 cells/kg) and cholecalciferol 2,000 UI/day for 6 months (group 1). Read More

View Article and Full-Text PDF

Characteristics of type 1 diabetes mellitus in children and adolescents with Down's syndrome in an admixed population.

Arch Endocrinol Metab 2021 Apr 29. Epub 2021 Apr 29.

Serviço de Endocrinologia Pediátrica, Departamento de Pediatria, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brasil,

Objective: People with Down's syndrome (DS) have a higher risk of developing type 1 diabetes mellitus (T1D) and may have specific clinical features compared to T1D patients without DS. This study evaluated the clinical and laboratory aspects of T1D in children and adolescents with DS in an admixed population.

Methods: A case-control study comparing patients with T1D and DS (T1D+DS) to patients with T1D without DS (T1D controls) from two tertiary academic Hospitals in São Paulo, Brazil. Read More

View Article and Full-Text PDF

Predicting Type 1 Diabetes Onset using Novel Survival Analysis with Biomarker Ontology.

AMIA Annu Symp Proc 2020 25;2020:727-736. Epub 2021 Jan 25.

IBM Research, NY, USA.

Type 1 diabetes (T1D) is a chronic autoimmune disease that affects about 1 in 300 children and up to 1 in 100 adults during their life-time. Improvements in early prediction of T1D onset may help prevent diagnosis for diabetic ketoacidosis, a serious complication often associated with a missed or delayed T1D diagnosis. In addition to genetic factors, progression to T1D is strongly associated with immunologic factors that can be measured during clinical visits. Read More

View Article and Full-Text PDF
January 2021

Modeling Disease Progression Trajectories from Longitudinal Observational Data.

AMIA Annu Symp Proc 2020 25;2020:668-676. Epub 2021 Jan 25.

IBM Research, Cambridge, Massachusetts, United States.

Analyzing disease progression patterns can provide useful insights into the disease processes of many chronic conditions. These analyses may help inform recruitment for prevention trials or the development and personalization of treatments for those affected. We learn disease progression patterns using Hidden Markov Models (HMM) and distill them into distinct trajectories using visualization methods. Read More

View Article and Full-Text PDF
January 2021

Endoplasmic Reticulum-Mitochondria Crosstalk and Beta-Cell Destruction in Type 1 Diabetes.

Front Immunol 2021 16;12:669492. Epub 2021 Apr 16.

Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands.

Beta-cell destruction in type 1 diabetes (T1D) results from the combined effect of inflammation and recurrent autoimmunity. In response to inflammatory signals, beta-cells engage adaptive mechanisms where the endoplasmic reticulum (ER) and mitochondria act in concert to restore cellular homeostasis. In the recent years it has become clear that this adaptive phase may trigger the development of autoimmunity by the generation of autoantigens recognized by autoreactive CD8 T cells. Read More

View Article and Full-Text PDF

Potential Mimicry of Viral and Pancreatic β Cell Antigens Through Non-Spliced and -Spliced Epitope Candidates in Type 1 Diabetes.

Front Immunol 2021 15;12:656451. Epub 2021 Apr 15.

Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.

Increasing evidence suggests that post-translational peptide splicing can play a role in the immune response under pathological conditions. This seems to be particularly relevant in Type 1 Diabetes (T1D) since post-translationally spliced epitopes derived from T1D-associated antigens have been identified among those peptides bound to Human Leucocyte Antigen (HLA) class I and II complexes. Their immunogenicity has been confirmed through CD4 and CD8 T cell-mediated responses in T1D patients. Read More

View Article and Full-Text PDF

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.

Front Immunol 2021;12:656362. Epub 2021 Apr 15.

Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences (DIBIC) L. Sacco, Università degli Studi di Milano, Milan, Italy.

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i. Read More

View Article and Full-Text PDF

Neuroskeletal Effects of Chronic Bioelectric Nerve Stimulation in Health and Diabetes.

Front Neurosci 2021 7;15:632768. Epub 2021 Apr 7.

Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United States.

Background/aims: Bioelectric nerve stimulation (eStim) is an emerging clinical paradigm that can promote nerve regeneration after trauma, including within the context of diabetes. However, its ability to prevent the onset of diabetic peripheral neuropathy (DPN) has not yet been evaluated. Beyond the nerve itself, DPN has emerged as a potential contributor to sarcopenia and bone disease; thus, we hypothesized that eStim could serve as a strategy to simultaneously promote neural and musculoskeletal health in diabetes. Read More

View Article and Full-Text PDF

In Vivo Confocal Microscopy Study of Corneal Nerve Alterations in Children and Youths with Type 1 Diabetes.

Pediatr Diabetes 2021 May 2. Epub 2021 May 2.

Department of Neuroscience, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.

Objective: To determine whether children and youths with type 1 diabetes (T1D) have early alterations of the corneal subbasal nerve plexus detectable with In vivo confocal microscopy (IVCM) and to investigate the role of longitudinally measured major risk factors for diabetes complications associated with these alterations.

Methods: One hundred and fifty children and youths with T1D and 51 age-matched controls were enrolled and underwent IVCM. Corneal nerve fiber length (CNFL), corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), corneal fiber total branch density (CTBD), and corneal fiber fractal dimension (CNFrD) were measured. Read More

View Article and Full-Text PDF

Type 1 Diabetes incidence among youth in Utah: A geographical analysis.

Soc Sci Med 2021 Apr 19;278:113952. Epub 2021 Apr 19.

Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.

Type 1 Diabetes (T1D) poses an increasing threat to public health, as incidence rates continue to rise globally. However, the etiology of T1D is still poorly understood, especially from the perspective of geography. The objective of this research is to examine the incidence of T1D among youth and to identify high-risk clusters and their association with socio-demographic and geographic variables. Read More

View Article and Full-Text PDF

Epigenetic changes related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for KDM2B.

Vaccine 2021 Apr 28. Epub 2021 Apr 28.

Background: A recent epigenome-wide association study of genes associated with type 2 diabetics (T2D), used integrative cross-omics analysis to identify 22 abnormally methylated CpG sites associated with insulin and glucose metabolism. Here, in this epigenetic analysis we preliminarily determine whether the same CpG sites identified in T2D also apply to type 1 diabetes (T1D). We then determine whether BCG vaccination could correct the abnormal methylation patterns, considering that the two diseases share metabolic derangements. Read More

View Article and Full-Text PDF

A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomised controlled trial.

Lancet Diabetes Endocrinol 2021 Apr 29. Epub 2021 Apr 29.

Quantitative Sciences Unit, Stanford University, Stanford, CA, USA; Department of Medicine, Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA; Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.

Background: There are few long-term studies of interventions to reduce in low socioeconomic status children with overweight or obesity. The Stanford GOALS trial evaluated a 3-year, community-based, multi-level, multi-setting, multi-component (MMM) systems intervention, to reduce weight gain among low socioeconomic status, Latinx children with overweight or obesity.

Methods: We did a two-arm, parallel group, randomised, open-label, active placebo-controlled trial with masked assessment over 3 years. Read More

View Article and Full-Text PDF

Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study.

Diabetes Ther 2021 May 1. Epub 2021 May 1.

Division of Endocrinology and Metabolism, Department of Medicine, Dalhousie University, Halifax, Canada.

Introduction: The aim of the study was to examine glycaemic control and safety of insulin degludec (degludec) in patients with either type 1 diabetes (T1D) or type 2 diabetes (T2D) under routine care settings in Canada.

Methods: Data were extracted from medical records of adults with T1D or T2D who switched to degludec (± prandial insulin) from another basal insulin (± prandial insulin) ≥ 6 months prior to data collection. The primary endpoint was change in glycated haemoglobin (HbA) at 6 ± 3 months after degludec initiation. Read More

View Article and Full-Text PDF

A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care.

Diabetes 2021 Apr 30. Epub 2021 Apr 30.

Benaroya Research Institute, Seattle, WA

The 2019 report of a randomized, placebo-controlled clinical trial demonstrating that immune therapy can delay the onset of clinical type 1 diabetes (T1D) in antibody-positive relatives by a median of 2 years stands out as a landmark in the decades-long effort to prevent T1D. With this important step achieved, it is now time to consider what is needed to bring disease-modifying therapy for prevention or delay of T1D to clinical use from this point. Long considered a chicken and egg problem (why screen for T1D risk when we have no therapy, and how can we develop therapies without more screening), we now have the opportunity to break this impasse. Read More

View Article and Full-Text PDF

Exploring the views of adolescents with type 1 diabetes on digital mental health interventions: what functionality and content do they want?

Diabet Med 2021 Apr 30:e14591. Epub 2021 Apr 30.

Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Background: Adolescents with type 1 diabetes (T1D) experience higher rates of psychological disorders compared to their healthy peers. As poor psychological health has been associated with sub-optimal glycaemic control and more frequent complications, there is an urgent need to develop more 'clinically usable' interventions. Digital mental health interventions offer unique advantages compared to in-person interventions, however, what adolescents with T1D want in terms of content and functionality is poorly understood. Read More

View Article and Full-Text PDF

Agreement between an Image-Based Dietary Assessment Method and a Written Food Diary among Adolescents with Type 1 Diabetes.

Nutrients 2021 Apr 16;13(4). Epub 2021 Apr 16.

Medical Research Center, Oulu University Hospital and University of Oulu, FI-90014 Oulu, Finland.

Valid and useful dietary assessment methods for adolescents with type 1 diabetes (T1D) are needed. In this study, we compared an image-based method with a written food diary for dietary intake estimation among adolescents with T1D and evaluated the adolescents' experiences of the methods. Adolescents with T1D aged 13 to 18 years ( = 13) photographed their meals ( = 264) with a mobile phone camera and simultaneously kept a written food diary for four consecutive days. Read More

View Article and Full-Text PDF

Physical Activity in Adolescents with and without Type 1 Diabetes during the New Zealand COVID-19 Pandemic Lockdown of 2020.

Int J Environ Res Public Health 2021 04 23;18(9). Epub 2021 Apr 23.

Department of Exercise Sciences, Faculty of Science, University of Auckland, Auckland 1023, New Zealand.

Physical activity (PA) is an important part of lifestyle management for adolescents with Type 1 diabetes (T1D). Opportunities for PA were reduced by COVID-19 restrictions. Therefore, the purpose of this cross-sectional study was to compare PA among adolescents with and without T1D during the first New Zealand (NZ) COVID-19 lockdown. Read More

View Article and Full-Text PDF

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.

Pharmaceutics 2021 Apr 2;13(4). Epub 2021 Apr 2.

Boehringer Ingelheim International GmbH, 55216 Ingelheim, Germany.

In clinical trials, sodium-glucose co-transporter (SGLT) inhibitor use as adjunct to insulin therapy in type 1 diabetes (T1D) provides glucometabolic benefits while diabetic ketoacidosis risk is increased. The SGLT2 inhibitor empagliflozin was evaluated in two phase III trials: EASE-2 and EASE-3. A low, 2. Read More

View Article and Full-Text PDF

Clinical Characteristics and Degree of Glycemic and Cardiovascular Risk Factor Control in Patients with Type 1 Diabetes in Catalonia (Spain).

J Clin Med 2021 Apr 6;10(7). Epub 2021 Apr 6.

DAP-Cat Group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), 08007 Barcelona, Spain.

Background: This study aims to evaluate the clinical characteristics, complications, degree of glycemic control, and cardiovascular risk factor control in patients with type 1 diabetes in Catalonia (Northwest of Spain).

Methods: Cross-sectional study using a database including clinical, laboratory, and treatment data. Patients with an ICD10 diagnosis of type 1 diabetes were included, excluding those treated with glucose-lowering agents other than insulin, or treated only with basal insulin two years after diagnosis. Read More

View Article and Full-Text PDF

Prevalence of psoriasis in a cohort of children and adolescents with type 1 diabetes.

J Eur Acad Dermatol Venereol 2021 Apr 29. Epub 2021 Apr 29.

Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Italy.

While there is clear evidence of an association between psoriasis and type 2 diabetes mellitus , limited information is available on the prevalence of psoriasis in children and adolescents with type 1 diabetes mellitus (T1D).. Read More

View Article and Full-Text PDF

Comparing Two Treatment Approaches for Patients with Type 1 Diabetes During Aerobic Exercise: a Randomised, Crossover Study.

Sports Med Open 2021 Apr 29;7(1):29. Epub 2021 Apr 29.

Waikato Medical Research Centre, Te Huataki Waiora, School of Health, University of Waikato, Hamilton, New Zealand.

Background: In a randomised, counterbalanced, crossover design, eight men with type 1 diabetes (T1D; mean ± SD age, 27.6 ± 11.4 years) reduced insulin (INS) by 50% of their normal dose or consumed carbohydrates equivalent to 1 g of carbohydrate per kilogramme of their body weight without the usual insulin bolus (CARBS) over two sessions, held a week apart. Read More

View Article and Full-Text PDF

Beneficial effects of physical exercise for β-cell maintenance in a Type 1 Diabetes mellitus animal model.

Exp Physiol 2021 Apr 29. Epub 2021 Apr 29.

Department of Cell and Developmental Biology, Institute of Biomedical Science (ICB), University of São Paulo (USP), São Paulo, Brazil.

New Findings: What is the central question of this study? Type 1 Diabetes mellitus (T1D) leads to hyperglycemia due a destruction of pancreatic β-cells by the immune system. Physical exercise has been shown to have potential beneficial protective roles against cytokine-induced pancreatic β-cell death, however its benefits are yet to be proven and should be better understood especially in the islet environment. What is the main finding and its importance? Physical exercise protects against β-cell loss in a well described animal model for T1D, induced by multiple-low-doses-streptozotocin. Read More

View Article and Full-Text PDF

Islet-Resident Dendritic Cells and Macrophages in Type 1 Diabetes: In Search of Bigfoot's Print.

Front Endocrinol (Lausanne) 2021 12;12:666795. Epub 2021 Apr 12.

Department of Diabetes Immunology, Diabetes & Metabolism Research Institute at the Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, United States.

The classical view of type 1 diabetes assumes that the autoimmune mediated targeting of insulin producing ß-cells is caused by an error of the immune system. Malfunction and stress of beta cells added the target tissue at the center of action. The innate immune system, and in particular islet-resident cells of the myeloid lineage, could function as a link between stressed ß-cells and activation and recognition by the adaptive immune system. Read More

View Article and Full-Text PDF

Neurokinin-1-tachykinin receptor agonist promotes diabetic fracture healing in rats with type 1 diabetes via modulation of Wnt/β-catenin signalling axis.

Saudi J Biol Sci 2021 Apr 17;28(4):2139-2145. Epub 2021 Feb 17.

Department of Geriatrics, Hengshui People's Hospital, Hengshui, Hubei 053000, China.

Diabetes mellitus is an ill-famed metabolic disorder with varied repercussions including delayed fracture healing. Wnt/β-catenin axis is known to play a tight pivotal role in the bone healing process. Substance P (SubP) is a neuropeptide with established positive modulatory functions in fracture healing and associated neuronal milieu. Read More

View Article and Full-Text PDF